Suppliers and packagers for zelboraf

zelboraf

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Hoffmann La Roche	ZELBORAF	vemurafenib	TABLET;ORAL	202429	NDA	Genentech, Inc.	50242-090-02	1 BOTTLE, PLASTIC in 1 CARTON (50242-090-02) / 112 TABLET, FILM COATED in 1 BOTTLE, PLASTIC	2011-08-17

Suppliers for the Pharmaceutical Drug: Zelboraf (Vemurafenib)

Last updated: July 30, 2025

Introduction

Zelboraf (vemurafenib) is an oral targeted therapy developed for the treatment of BRAF V600E mutation-positive metastatic melanoma. Since its FDA approval in 2011, Zelboraf has become a cornerstone in precision oncology, offering a targeted approach that inhibits mutated BRAF kinase. The supply chain for Zelboraf involves multiple stages, including active pharmaceutical ingredient (API) manufacturing, formulation, distribution, and regulatory oversight. This article explores the key suppliers across these stages, analyzing their roles, market positioning, and implications for stakeholders.

Active Pharmaceutical Ingredient (API) Suppliers

The foundation of Zelboraf’s supply chain lies in its API, vemurafenib. The API's quality, stability, and regulatory compliance are critical to product efficacy and safety. Several companies are involved in API production globally, though detailed public disclosures about specific API suppliers for Zelboraf are limited due to proprietary considerations.

1. Original API Manufacturers

AstraZeneca, the innovator behind Zelboraf, initially outsourced API manufacturing to reputable pharmaceuticals and specialty chemical producers. The company emphasizes strict quality assurance aligned with Good Manufacturing Practices (GMP). Over time, AstraZeneca has diversified its supplier base to mitigate risks associated with supply disruptions.

2. Contract Manufacturing Organizations (CMOs)

CROs and CMOs play pivotal roles in API production, especially for complex syntheses like vemurafenib. Notable players include:

• Fujifilm Diosynth Biotechnologies: Known for high-volume API manufacturing, with GMP compliance and scalable processes.
• Patheon (a division of Thermo Fisher Scientific): Offers CMO services that include synthesis, purification, and scale-up for small molecules like vemurafenib.
• Lonza: Specializes in active ingredients and offers contract manufacturing with robust quality systems compliant with international standards.

The choice of API suppliers impacts Zelboraf's cost, quality, and supply stability, making due diligence, qualification, and ongoing auditing essential.

Formulation and Finished Dosage Form Suppliers

Once API manufacturing is complete, formulation into the final dosage form involves excipient sourcing, mixing, compression, and packaging. This process typically involves licensed pharmaceutical contract manufacturers.

1. Formulation Contract Manufacturers

Major CDMOs involved in Zelboraf formulation include:

• Hutchison China MediTech (Hutchmed): Known for specialized oncology formulations, including small molecule targeted therapies.
• Samsung Biologics: While primarily known for biologics, Samsung also supplies small molecule formulation services.
• Capsugel (now part of Lonza): Provides capsule manufacturing and specialized excipients.

2. Packaging and Distribution

Zelboraf is packaged in blister packs and distributed globally through AstraZeneca's extensive commercial network. Packaging suppliers ensure stability, tamper-evidence, and compliance with regulatory standards.

Distribution and Logistics Suppliers

Adequate distribution is vital for maintaining drug integrity and access. Key players:

• McKesson and Cardinal Health: Major pharmaceutical distributors in North America.
• UPS and DHL: Global logistics providers specializing in temperature-controlled transport for sensitive pharmaceuticals.
• Kuehne + Nagel: Provides specialized supply chain solutions for pharmaceuticals, including cold chain logistics.

The reliance on temperature-controlled logistics underpins the importance of trustworthy, compliant logistics providers to prevent degradation and ensure timely delivery.

Regulatory and Quality Assurance

Suppliers must adhere to stringent regulatory standards set by authorities such as the FDA (United States), EMA (Europe), and PMDA (Japan). Regulatory compliance involves:

• Validated manufacturing processes.
• Documentation of quality control (QC) and quality assurance (QA).
• Traceability of raw materials and components.
• Regular audits and inspections.

Independent quality assurance providers and regulatory consultants support patent holders in maintaining compliance, indirectly influencing the supplier landscape.

Global Supply Chain Considerations

The globalized nature of pharmaceutical manufacturing introduces susceptibility to geopolitical shifts, trade regulations, and supply disruptions. AstraZeneca’s strategy includes:

• Diversification in supplier sourcing.
• Building regional manufacturing hubs.
• Engaging multiple CMOs for API and formulation to mitigate risks.

The ongoing COVID-19 pandemic underscored these vulnerabilities, prompting manufacturers to develop more resilient supply networks.

Intellectual Property and Market Dynamics

While APIs often involve proprietary processes, patent protections and exclusivity rights influence the supplier ecosystem. As patents expire, generic manufacturers may enter the market, altering supplier dynamics and pricing strategies, potentially impacting existing supply arrangements.

Conclusion

The supply chain for Zelboraf involves a complex network of API producers, formulation specialists, logistic providers, and regulatory partners. While specific supplier identities are often confidential, the involvement of key CMOs and logistics firms indicates a diversified, quality-focused approach. Ensuring supply stability depends on ongoing supplier qualification, compliance with international standards, and proactive risk management strategies.

---

Key Takeaways

• Diversification is crucial: AstraZeneca's multi-supplier approach for API and formulation reduces supply chain risks.
• Regulatory compliance is non-negotiable: Suppliers must meet GMP standards for quality and safety.
• Resilient logistics are vital: Temperature-controlled, global logistics providers safeguard drug integrity and ensure timely delivery.
• Market dynamics influence supply: Patent expirations open opportunities for generics, impacting supplier relationships and pricing.
• Strategic sourcing enhances stability: Building regional manufacturing capacity and multi-sourcing strategies mitigate geopolitical and pandemic-related disruptions.

---

FAQs

1. Who are the primary suppliers of vemurafenib API for Zelboraf?
While specific names are proprietary, AstraZeneca historically outsourced API manufacturing to specialized pharmaceutical CMOs such as Fujifilm Diosynth and Lonza, with ongoing diversification to mitigate supply risks.

2. Are there generic versions of Zelboraf?
Yes, following patent expirations and market exclusivity lapses, generic manufacturers have begun producing vemurafenib, altering the supply landscape and pricing.

3. How does the supply chain ensure the quality of Zelboraf?
Through stringent GMP compliance, rigorous supplier qualification, routine audits, and continuous regulatory oversight, ensuring the API, formulation, and packaging meet safety and efficacy standards.

4. What logistical challenges exist in supplying Zelboraf globally?
Maintaining temperature-controlled supply chains, managing customs and regulatory approvals, and ensuring timely delivery to remote regions are key challenges.

5. How might geopolitical factors affect Zelboraf’s supply?
Trade restrictions, regional manufacturing policies, and geopolitical tensions can disrupt supply chains, emphasizing the importance of diversified sourcing and regional manufacturing hubs.

---

References

1. [1] AstraZeneca Official Website. "Zelboraf (vemurafenib) prescribing information."
2. [2] U.S. Food and Drug Administration (FDA). "Zelboraf (vemurafenib) approval details."
3. [3] European Medicines Agency (EMA). "Regulatory status of Vemurafenib."
4. [4] Pharmaceutical Technology. "Contract Manufacturing Organizations involved in small molecule API production."
5. [5] Industry reports on pharmaceutical supply chains and logistics.